Alex Burgin

Alex Burgin is the Senior Director of the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. CDoT is a professional drug discovery organization that works with Broad faculty and industry partners to advance novel drug discovery projects. Burgin has over 30 years’ experience spanning both academia and the private sector. Burgin completed his postdoctoral training at the National Institutes of Health and was Group Leader at Ribozyme Pharmaceuticals prior to joining the faculty of San Diego State University, where he ran an active research and training program. He then joined Emerald BioStructures (now UCB Pharma) where, as Chief Operating Officer and then as Chief Scientific Officer, he led multiple drug discovery projects. After leaving industry, Burgin served as the Senior Scientific Advisor to the Broad’s Chief Scientific Officer and was named an Institute Scientist. Burgin served as the Executive Director at the Institute for Protein Innovation before returning to the Broad. Burgin holds an A.B. from Wabash College and a Ph.D. in genetics from Indiana University.